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Abstract: The genetic landscape of Parkinson’s disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a signif-
icant minority in PD cases and high frequency, low penetrance variants, which contribute a small
increase of the risk of developing sporadic PD. This knowledge has the potential to have a major
impact in the clinical care of people with PD. We summarise these genetic influences and discuss the
implications for therapeutics and clinical trial design.
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1. Introduction
Parkinson’s disease (PD) is a neurodegenerative condition affecting over 6 million
people worldwide that is expected to double in prevalence by 2040 [1]. It is characterised
by a core set of movement (motor) abnormalities - slowness of movement, muscle rigidity
and tremor – as well as a number of non-motor features such as constipation, anxiety and
dementia [2]. There is often a prodromal phase of non-motor symptoms which precede
motor symptoms by many years [3]. The pathological hallmark of PD is Lewy bodies,
which are aggregates of misfolded α-synuclein protein (encoded by the SNCA gene) which
lead to the loss of midbrain dopamine-producing neurons. However, diagnostic criteria
for PD are based on clinical features alone [4,5]. PD can therefore be considered a clinical
syndrome with aetiological pathways that converge onto a common final presentation
of dopamine loss and clinical Parkinsonism. There are currently no disease-modifying
therapies for PD and treatment focusses on dopamine replacement to alleviate symptoms.
The exact cause of PD is unknown. Early twin studies showed only a slight excess
of PD in monozygotic compared to dizygotic twins and led to the conclusion that PD
was an exclusively acquired condition [6]. However, the discovery of a familial form of
PD due to a single gene mutation [7] and later twin studies incorporating a longitudinal
design [8,9] have led to the current paradigm of PD as a complex disease with both genetic
and environmental contributions [10]. Meta-analysis suggests that the presence of a family
history of Parkinson’s confers a 3–4× increase in PD risk, implying a significant effect of
shared genetic and environmental factors to sporadic PD risk [11].
Age is known to be the greatest risk factor for developing PD [12]. The age-related
decline in midbrain dopamine-producing neurons may reach a threshold below which
clinical symptoms emerge and an individual’s total number of dopaminergic neurons may
therefore contribute to the risk and age of onset of PD [13]. A number of environmental ex-
posures have also been associated with PD in observational studies including head trauma,
dairy consumption and pesticide exposure [14]. Cigarette smoking and caffeine consump-
tion have been associated with reduced risk of PD, although the biological mechanisms for
this remain unclear [15,16].
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Genetic variation is estimated to contribute approximately 25% to the overall risk of
developing PD [9,17,18]. The genetic variants related to PD vary in terms of frequency and
risk of PD (Figure 1). On the one hand, there are a number of rare variants in single genes
that are sufficient to cause disease (i.e., are pathogenic). These monogenic causes of PD
were predominantly identified through linkage analysis of affected families. Examples of
such genes include SNCA, PARK7 and PRKN. On the other hand, genome wide association
studies (GWAS) have identified large numbers of common genetic variants that individually
contribute a small amount to the risk of developing PD. In the middle of this spectrum lie
variants that are uncommon (but not rare) and exert an intermediate risk, such as GBA and
LRRK2 variants.
Figure 1. Summary of genetic variants in Parkinson’s disease grouped according to allele frequency
and associated risk of Parkinson’s disease.
Genetics provides one way in which PD can be subdivided. Different subgroups may
have separate aetiologies, treatments and prognosis [19]. Common stratification factors for
PD include age of onset (early- vs late-onset PD, typically with a cut-off of 50 years of age),
the presence or absence of family history (familial vs sporadic PD) and the presence of
pathogenic variants (monogenic vs idiopathic PD). Truly monogenic forms of PD are very
rare and may not represent the same disease processes that occur in idiopathic PD. For in-
stance, PRKN, PINK1 and PARK7 are all genomic regulators of mitochondrial function [20].
This is important to consider as the majority of laboratory models have focussed on path-
ways that were identified by monogenic causes of PD [21]. Encouragingly, some of the
common variants identified in GWAS also implicate genes that cause monogenic PD [21].
For instance, common variants at the SNCA loci exert the largest contribution to PD risk
in GWAS and rare SNCA variants are a cause of monogenic PD, supporting the existing
α-synuclein centric model of PD [18]. Conversely the MAPT loci encodes tau, aggregates
of which are found in a range of neurodegenerative diseases such as Alzheimer’s disease,
frontotemporal dementia and progressive supranuclear palsy, suggesting the involvement
of other pathways in PD pathogenesis [18,22].
An understanding of the genetic factors influencing a disease process can have major
impacts on clinical care. Firstly, it can identify causative genes and highlight biological
pathways important to pathogenesis. This in turn can allow the development of therapeu-
tics which target those biological pathways. Secondly, it can allow diverse presentations of
disease to be accurately subdivided into groups of shared genetic causes. This is essential
for ‘precision medicine’, where management strategies are focussed on an individual’s
specific disease subtype. Finally, greater knowledge of the effect of genetic variants on
the risk, onset and progression of disease means the implications and prognosis can be
discussed frankly with individuals, who are then empowered to make educated decisions.
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This review will first summarise the monogenic and polygenic variants associated
with PD and then discuss the clinical implications of this knowledge. We shall also draw
parallels with diabetes where appropriate to highlight how this knowledge may shape and
influence disease management.
2. Monogenic Parkinson’s Disease
A range of loci and genes have been associated with PD phenotypes in a Mendelian
fashion and were originally designated a ‘PARK’ locus with the number representing the
chronological order of discovery. However, multiple PARK loci can refer to the same gene
(e.g., PARK1 and PARK4 both refer to SNCA) and some early PARK loci are no longer
thought to be disease-causing (e.g., PARK5). Current recommendations are to use gene
names in preference to numbered loci [23], although it is important to be aware of this
previous nomenclature and the alternative gene names are listed in Table 1 for clarity.




Gene Names Inheritance Pathogenicity PD Phenotype Function
High
penetrance
SNCA PARK1,PARK4, NCAP AD Pathogenic Early-onset
Uncertain (encodes
α-synuclein)




PINK1 PARK6 AR Pathogenic Early-onset
MitochondrialPARK7 DJ-1 AR Pathogenic Early-onset
PRKN PARK2,PARKIN AR Pathogenic Early-onset
PLA2G6 PARK14,IPLA2 AR Pathogenic Early-onset, atypical Cell membrane
ATP13A2 PARK9 AR Pathogenic Early-onset, atypical Lysosomal
FBXO7 PARK15,FBX7 AR Pathogenic Early-onset, atypical Mitochondrial
POLG POLG1,POLGA AD Pathogenic Early-onset, atypical
Mitochondrial
DNA maintenance







TMEM230 C20ORF30 AD Conflictingreports Typical
SYNJ1 PARK20 AR Pathogenic Early-onset, atypical
VPS13C PARK23 AR Pathogenic Early-onset Mitochondrial
CHCHD2 - AD Pathogenic Typical Uncertain
DCTN1 - AD Pathogenic Atypical Microtubule
Variable
penetrance










HTRA2 - AD Uncertain/likelybenign - Mitochondrial
UCHL1 PARK5 AD Uncertain/likelybenign -
Ubiquitin-
proteasome
GIGYF2 PARK11 AD Uncertain/likelybenign - Uncertain
EIF4G1 - AD Benign - mRNA translation
LRP10 LRP9 AD 1 Uncertain - Uncertain
1 AD = autosomal dominant, AR = autosomal recessive, HNGC = HUGO Gene Nomenclature Committee.
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Variants with high penetrance are very rare whereas those with variable penetrance
are more common worldwide, particularly in specific populations. Table 1 summarises
these genes, including those historically associated with PD pedigrees in which subsequent
conflicting reports and lack of segregation mean the evidence for pathogenicity is low.
2.1. Single Genes with High Penetrance
2.1.1. SNCA
The first monogenic cause of PD was discovered in a large Italian family with an
autosomal dominant pattern of PD presenting with typical clinical features but early
onset (median age 46 years). Linkage studies identified an area of chromosome 4q that
segregated with the disease [24]. Candidate gene sequencing of this region subsequently
demonstrated a missense variant (c.209G>A) in the α-synuclein gene (SNCA) which causes
an amino acid substitution (p.A53T) [7]. The same missense variant was found in unrelated
Greek pedigrees. Subsequent studies of familial and sporadic PD cohorts suggest it is
an extremely a rare cause of PD overall [25,26]. Other missense SNCA variants have
since been discovered including p.A30P [27], p.E46K [28] and p.G51D [29]. Duplications
and triplications of SNCA can also cause PD with evidence for a ‘dosage effect’, where
greater expression of α-synuclein leads to more severe clinical features [30,31]. However,
pathogenic SNCA variants only account for a tiny proportion of PD cases [32–34].
α-synuclein is highly expressed in the brain and localises predominantly to pre-
synaptic terminals of neurons. The discovery that α-synuclein is the major component of
Lewy bodies identified a link between the genetic and pathological features of PD [35]. A
range of laboratory and animal studies have established that α-synuclein can form abnor-
mal aggregates which are neurotoxic [36–38]. α-synuclein aggregates are able to spread
within the central nervous system with the fibril form being particularly toxic. Different
clinical features are observed depending on the form and location of abnormal α-synuclein
aggregates [39]. This aggregation process is accelerated by SNCA pathogenic variants or by
an increase in intracellular alpha synuclein concentration disrupting proteasome function
and exacerbating oxidative stress [40,41].
Despite the rarity of pathogenic SNCA variants, the relevance of α-synuclein to both
monogenic and idiopathic forms of PD has been established by the presence of Lewy bodies,
the altered expression of SNCA in neurons of people with idiopathic PD [42] and the SNCA
loci identified in GWAS studies of idiopathic PD (see Section 3.). A number of overlapping
functions for α-synuclein have been proposed with interactions demonstrated with other
monogenic PD gene products and involvement in multiple pathways including synap-
tic vesicle function, lysosomal function, mitochondrial function and inflammation [43].
Therefore the biological pathways of α-synuclein aggregation have become the central
hypothesis for the molecular processes causing PD.
2.1.2. VPS35
Independent exome sequencing studies in 2011 identified a missense variant in the
VPS35 gene (p.D620N) of Swiss [44] and Austrian [45] families with an autosomal dominant
pattern of PD that cosegregrated within the family and was not present in healthy controls.
VPS35 encodes a component of the multimeric retromer complex which mediates trafficking
of endosomes. It appears to be important in neuronal transport to dendrites [46] and
neuronal cells from humans with the p.D620N variant show disrupted endosomal transport
and abnormal accumulation of α-synuclein and reactive oxygen species [47,48]. Although
pathogenic variants in VPS35 are particularly rare, comprising only 0.2% of European
patients with suspected autosomal dominant PD, patients manifest typical PD symptoms
with a good response to L-DOPA [49,50]. It is reasonable to consider that the gene function,
particularly with its association with α-synuclein and mitochondrial function, is also
implicated in sporadic PD.
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2.1.3. PRKN/ PARK7/ PINK1
These genes will be considered together as their protein products are linked to mito-
chondrial function and biallelic variants all cause autosomal recessive forms of PD. Between
1998 and 2004, studies of families, often consanguineous, affected by early-onset forms
of PD with a suspected autosomal recessive inheritance pattern identified biallelic loss
of function variants in PRKN (previously called Parkin) [51], PARK7 (previously called
DJ-1) [52] and PINK-1 [53]. PRKN encodes Parkin which is a ubiquitin ligase involved
in the proteasomal degradation system [54] and also has a role in the maintenance of
mitochondrial structure and DNA integrity [55]. PARK7 encodes the DJ-1 protein (or
Parkinson disease protein 7) whose specific function is unclear but has been shown to
interact with a number of proteins including tau [56], Parkin and PINK1. The product of
PINK1, PTEN-induced kinase 1, is a mitochondrially associated kinase that may have an
anti-inflammatory role in animal models [57]. Parkin, DJ-1 and PINK1 form a ubiquitin
ligase complex whose function is impaired by pathogenic variants [58]. Taken together, the
evidence suggests that Parkin, DJ-1 and PINK1 interact within the ubiquitin-proteasome
system and have a role in the maintenance of mitochondrial structure. Autopsy studies
have shown variable results with respect to Lewy body pathology in these genetic forms
of PD. In particular, initial studies demonstrated a lack of Lewy bodies in patients with
biallelic PRKN mutations, questioning its relevance to sporadic PD [59–61]. However,
subsequent case reports have identified Lewy bodies in homozygous and heterozygous
cases of PRKN-PD [62,63].
2.1.4. Others
A number of other genes have been implicated in monogenic PD (see Table 1) but
either result in a complex phenotype with significant features in addition to Parkinsonism
or have less robust evidence for pathogenicity.
ATP13A2 biallelic variants result in adolescent-onset PD with dementia and hallu-
cinations [64]. The protein is involved in lysosomal function [65]. Biallelic variants in
the FBXO7 gene have been associated with an early-onset form of PD with pyramidal
signs [66–68] and FBXO7 interacts with PINK1 to enable its degradation [69]. Biallelic
variants in the phospholipase-encoding PLA2G6 gene were originally described in neu-
rodegeneration with brain iron accumulation but can also cause autosomal recessive PD
with or without cognitive, pyramidal and dystonic features [70–72]. DNAJC6 and SYNJ1
encode interacting proteins involved in synaptic vesicle recycling and result in early-onset
autosomal recessive forms of PD [73,74]. DNAJC13 and TMEM230 also have a role in
synaptic vesicle processing, but variants were discovered in the same affected PD pedigree
and their pathogenicity remains uncertain [75].
Some genes have only been reported in single pedigrees plus isolated cases (e.g., TMEM230
variants [75,76]) or have conflicting presence in healthy controls (e.g., UHCL1, HTRA2 [77]).
These could represent variants with reduced penetrance or simply erroneous associations
with disease.
2.2. Single Genes with Variable Penetrance
LRRK2 and GBA have been associated with familial PD. GBA in particular does
not tend to demonstrate a Mendelian (i.e., autosomal recessive or dominant pattern) of
inheritance. They can either be considered as genetic ‘risk factors’, where the presence
of certain variants confers an increased risk developing PD, or as autosomal dominant
pathogenic variants with incomplete penetrance. The distinction is somewhat arbitrary,
particularly when different variants are considered, as some display high penetrance and
could be considered monogenic causes of PD.
2.2.1. LRRK2
Heterozygous missense LRRK2 variants were originally identified in families with
autosomal dominant patterns of PD inheritance [78,79]. Subsequent work has identified
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the c.6055G>A variant (p.G2019S) as the most common pathogenic variant worldwide. It
is particularly common in Ashkenazi Jewish and North African Berber populations with
prevalence rates, respectively, as high as 26% and 41% in some cohorts. The risk of PD
by aged 80 years in carriers of the p.G2019S variant is estimated to be 25–74% [80–82].
A number of other pathogenic LRRK2 variants have been described. Some have been
described through linkage studies in kindreds with Parkinson disease with an autosomal
dominant pattern of inheritance, whilst other appear to exert marginal increases in PD,
characterised by genetic case control data [83,84]. This hints at significant heterogeneity of
PD risk associated with individual LRRK2 variants, although our understanding of this is
certainly not as developed as in the case of GBA.
Both environmental (e.g., cigarette smoking, non-steroidal anti-inflammatories) and
genetic modifiers have been proposed as factors to explain this incomplete penetrance [85–87].
Penetrance of LRRK2-PD varies between Arab Berbers and Norwegians, whereas age of
onset of idiopathic PD does not, suggesting disparate genetic and environmental modifiers
in LRRK2-PD penetrance [88]. Conversely, some studies have suggested a lower penetrance
amongst Ashkenazi Jewish p.G2019S subjects, although this difference in penetrance may
reflect varying degrees of ascertainment bias (i.e., where carriers were identified on this
basis of being blood relatives of an index case with PD and may carry genetic cofactors
that increase PD risk) [81]. The PD polygenic risk score modifies LRRK2-PD penetrance
and 1 significant individual locus has been identified that modifies penetrance (within the
CORO1C gene) [89]. The risk of PD varies according to the specific LRRK2 variants and
certain variants, such as p.R1398H, appear to exert a protective effect [90].
The clinical phenotype of LRRK2-PD is broadly similar to that of idiopathic PD with
a good response to L-DOPA and a median age of onset of 57 years. However, there is
contradictory evidence as to the specific phenotype of LRRK2-PD. Some studies suggest that
p.G2019S LRRK2 variants may have higher rates of motor complications [83,91]. One large
study suggests a more benign clinical course with a tremor predominant phenotype [82],
although other studies do not replicate this finding [81]. The identification of LRRK2
missense variants in ~1% of sporadic PD and LRRK2 loci in GWAS, suggests that LRRK2
has an important role in idiopathic as well as LRRK2-PD.
LRRK2 encodes the leucine-rich repeat kinase 2 protein which has both kinase and
GTPase domains. Its physiological role is thought to include autophagy, mitochondrial
function and microtubule stability [92]. Pathogenic variants lead to increased kinase do-
main activity, raising the tantalising possibility of pharmacological inhibition as a possible
therapeutic strategy [93,94]. Moreover, LRRK2 kinase activity is enhanced in post-mortem
brain tissue of people with idiopathic PD who lack LRRK2 variants [95]. Despite animal
models suggesting off target effects of LRRK2 inhibition [96,97], the apparent benign pres-
ence of heterozygous loss of function LRRK2 variants in humans is reassuring that partial
reduction in LRRK2 function is safe [98,99].
2.2.2. GBA
Biallelic (i.e., homozygous or compound heterozygous] variants in the GBA gene can
lead to Gaucher disease, a lysosomal storage disorder caused by reduced activity of the
GBA-encoded enzyme glucocerebrosidase (GCase). Its relevance to PD was first considered
when patients with Gaucher disease were noted to develop disproportionate levels of
Parkinsonian features [100]. The observation of high rates of PD in the families of those with
Gaucher disease suggested that heterozygous GBA variants cause PD independently [101].
Case-control studies across various populations confirmed an increased risk of PD in those
with GBA variants [102].
Unhelpfully, two nomenclatures which include or omit a 39 amino acid leader of the
GBA gene exist. Here we refer to the more commonly used historical classification, with
the newer classification (which complies with HGNC guidelines) in brackets.
The range of GBA variants identified (to date over 200 Gaucher causing GBA variants
have been documented [103,104])complicates estimation of PD risk. High quality prospec-
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tive data amongst those with a diagnosis of Gaucher disease suggest that by 80 years the
penetrance of PD is approximately 10% [105]. As with LRRK2, it is likely that ascertainment
bias has inflated risk estimates of PD penetrance in at least some cohorts [106,107]. Overall
genetic case control data suggests that eleven [predominantly missense] individual GBA
variants increase PD risk [108]. p.N370S (p.N409S) and p.L444P (p.L483P) are the most
common worldwide, with the p.N370S (p.N409S) variant particularly seen in Ashkenazi
Jewish populations [109]. Respectively, they increase the risk of PD by ×4 and ×12. A
number of meta-analyses have also estimated cumulative risks associated with all GBA mu-
tations, but the significant heterogeneity of penetrance of individual GBA variants makes
these estimates of limited usefulness [102,108]. Stratification of PD risk of GBA variants
based on the Gaucher disease phenotype [namely the presence or absence of neurological
features associated with them] provides a more relevant estimate of risk. Aggregated
‘mild’ variants increase PD risk by ×3 compared to the general population, whilst ‘severe’
variants (associated with neurological GD features) increase this risk by ×15 [110]. p.E326K
(p.E365K) and p.T369M (p.T408M), found commonly in European populations, double PD
risk compared to the general population, but do not cause Gaucher disease [108,111–113].
Collectively 10–15% of European PD patients carry a PD associated GBA variant, making it
numerically the most significant PD genetic risk factor by some distance [33].
Similarly to LRRK2, both environmental and genetic cofactors are postulated to explain
the reduced penetrance of GBA variants. A recent GWAS of individuals with GBA variants
with and without PD showed that the PD risk loci implicating SNCA and CTSB were
significantly associated with GBA-PD [114]. CTSB encodes a lysosomal protease which
may interact with GCase.
The closely related GBAP pseudogene has important implications for the study of GBA,
as certain sequencing techniques are required to identify specific GBA variants. Depending
on the techniques used, studies may only report on specifically targeted variants and miss
other variants present in the GBA gene [115]. By using a PCR enrichment step, both Illumina
based sequencing by synthesis [116]and long read sequencing using the Oxford Nanopore
has been shown to reliably screen the entire GBA gene. The latter has been reliably able to
phase variants, which is a distinct advantage, because quite a number of pathogenic GBA
variants are in fact complex haplotypes derived from reciprocal translocations with the
GBA pseudogene [117].
The clinical phenotype of GBA-PD is similar to that of idiopathic PD, although there is
robust evidence that GBA variants in those with PD confer an earlier age of onset, higher
rates of dementia and faster progression of motor symptoms [99,118–121]. ’Severe’ GBA
variants are associated with more exaggerated clinical features [110]. This is also the
case when variant pathogenicity is predicted with in silico methods [122]. Importantly,
both p.E326K (p.E365K) and p.T369M(p.T408M), are associated with an increased risk
of cognitive impairment and more rapid disease progression [123,124], in spite of the
relatively small increase in PD risk associated with them.
In contrast to many of the other genes implicated in monogenic PD, the biological
role of GBA is well understood. GCase is a lysosomal hydrolase that breaks down glu-
cosylceramide into ceramide and glucose. GBA variants have differential effects on both
the enzymatic activity of GCase and its trafficking within cells [125]. This identifies both
enzyme action and cellular trafficking of GCase as potential therapeutic targets. Blood,
cerebrospinal fluid (CSF) and brain GCase activity levels have been shown to be lower in
idiopathic PD as well as GBA-PD, suggesting that novel GBA targeted therapies may also
be beneficial in idiopathic PD [126–128].
2.2.3. Heterozygous PRKN as a PD Genetic Risk Factor
Although bialleic PRKN variants are an established cause of PD, considerable con-
troversy surrounds the effect on PD risk of heterozygous PRKN variants. Heterozygous
PRKN variants are common finding amongst those with PD. One large study found that
some 1.2% of early onset/familial PD cases carry a PRKN variant [33]. The same study
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found that PRKN carriers had an age at onset some 12 years lower than PD cases without
other genetic risk factors. There is, however, conflicting data regarding the effect they exert
on PD risk. A number of small studies suggest PRKN variants do increase PD risk however
no association has been found in other studies [129] including in a recent analysis of some
2807 patients and 3627 controls [130–132]. It may be that only a portion of PRKN variants,
and in particular those with a truncating effect on protein function, confer an effect of PD
risk. This may explain the discontinuity of results seen.
3. Sporadic Parkinson’s Disease
In contrast to studies of familial PD that initially identified monogenic associations
through studies of affected pedigrees, the genetics of sporadic PD has primarily advanced
through case-control GWAS of common genetic variants. GWAS are powerful techniques to
identify genetic loci that have a small but additive effect on traits of interest and can identify
biological pathways relevant to that trait. The combined effect of multiple common genetic
variants (typically defined as a minor allele frequency of greater than 5%) contributes to
the risk of developing a common disease, such as sporadic PD. Whereas twin studies show
greatest PD heritability when onset is below 50 years (capturing the highly penetrant but
rare monogenic causes), GWAS heritability is greatest in those with PD onset over 50 years,
demonstrating that common variants have the greatest genetic contribution to the risk of
late-onset PD [9,17].
Table 2 summarises GWAS of idiopathic PD performed to date according to the Na-
tional Human Genome Research Institute GWAS Catalog [133]. The majority of idiopathic
PD-related GWAS have focused on variants associated with the risk of developing PD.
Only a minority have interrogated possible associations with other traits such as age of PD
onset, progression of disease or response to medications. Furthermore, most studies have
used European cohorts thus limiting the applicability of results to worldwide populations.
Table 2 demonstrates that the larger the GWAS cohort, the greater the number of significant
loci identified. This has also been shown for other common continuous traits such as height
and body mass index [134] and also other binary disease states such as type 2 diabetes [135].
The information from these GWAS can be utilised in two main ways: firstly, the biological
functions captured by associated variants can identify underlying disease mechanisms;
secondly, the combined information from all associated variants can produce a ‘polygenic
risk score’ to quantify an individual’s genetic risk of developing a trait.
GWAS have identified new genes relevant to the risk of developing PD. However,
the actual functional effect indicated by trait-associated variants can be challenging to
determine. Moreover, significant variants tag a genomic region with which that variant is
in linkage disequilibrium and most common variants are found in non-coding regions of
the genome. Therefore, post-GWAS analyses are critical in assigning biological function
to GWAS variants. Examples of post-GWAS analyses include pathway analysis (where
groups of variants are analysed together to determine the relevance of sets of gene to
the trait] and expression quantitative trait loci (eQTL) analysis (which identifies variants
associated with the expression of genes and so identifies a regulatory element) [136]. In
PD, robust associations from multiple GWAS and subsequent post-GWAS analyses have
been identified for SNCA, RAB29, MAPT, BST1, GAK, LRRK2 and HLA-DRB5 amongst
others [18,137]. GAK has a role in synaptic endocytosis and so links this pathway in
sporadic PD to the rare forms of DNAJC6 and SYNJ1 monogenic PD. Intriguingly, some of
these genes harbour common variants that increase risk to sporadic disease as well as rare
variants that cause monogenic PD, indicating shared biological pathways (e.g., SNCA).
A polygenic risk score (PRS) allows the combined effect of GWAS variants to be
quantified in an individual. A PRS will therefore depend on the variants included and will
be specific to the cohort ethnicity and to the trait under consideration. Using the variants
from Nalls et al. [18] there is approximately 4 times greater odds of PD in the highest PRS
quartile compared with the lowest quartile. Additionally, the PD risk PRS has consistently
been shown to correlate with age of onset in multiple ethnicities, despite the fact that PD
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age of onset GWAS have found very few significant variants [138–141]. A study using
an Asian cohort demonstrated that an ethnicity-specific PRS enhances performance [142].
Despite this consistent association of PRS with disease state and age of onset, addition
of PRS to clinical decision tools only has a limited impact [141,143]. A recent study used
a novel approach to assess association between the PRS of genes within pre-specified
functional pathways and the risk of PD and identified 46 significantly associated pathways,
including 6 that did not involve any of the previously identified GWAS loci [144].
Despite this progress in identifying many common variants associated with PD risk,
GWAS can still only account for 16–36% of PD heritability [18]. In the future, we anticipate
that larger cohorts incorporating different ethnicities will identify more lower risk variants
and that assessing different PD-related traits will further contribute to the polygenic
architecture of PD. However it is important to emphasize that GWAS is of limited use
for the identification of some genetic risk factors, for example GBA. Because it relies
upon arrays of directly genotyped variants and then imputes other variants by linkage
disequilibrium, important disease associated variants can be missed. In fact, GWAS was
only able to identify the GBA locus using a candidate gene approach [145]. It may be that
other such genetic risk factors contribute to PD risk but remain undetected by current
GWAS analyses. Expanding our understanding of these genetic contributors to idiopathic
PD risk is likely to require forensic examination of sequencing data, a time consuming,
expensive and highly complex process [146].
Table 2. Summary of idiopathic Parkinson’s disease GWA studies included in NHGRI-EBI Catalog of human genome-wide
association studies.




Fung et al. [147] 2006 267:270 PD European 0
Pankratz et al. [148] 2009 857:867 Familial PD European 0
Latourelle et al. [149] 2009 1604:440 PD age of onset European 0
Satake et al. [150] 2009 1921:18274 PD East Asian 4
Simón-Sánchez et al. [151] 2009 5074:8551 PD European 3
Edwards et al. [152] 2010 1752:1745 PD European 2
Hamza et al. [153] 2010 2000:1986 PD European 4
Saad et al. [154] 2011 4271:9048 PD European 2
Simón-Sánchez et al. [155] 2011 772:2024 PD European 0
Liu et al. [156] 2011 2050:1836 PD European 0
Spencer et al. [157] 2011 2744:7159 PD European 3
Nalls et al. [158] 2011 12386:21026 PD European 11
Do et al. [159] 2011 3426:29624 PD European 8
Chung et al. [160] 2012 443:0 PD motor andcognitive outcomes European 0
Hernandez et al. [161] 2012 387:496 Early-onset PD Finnish 0
Pankratz et al. [145] 2012 7976:6350 PD European 5
Davis et al. [162] 2013 31:767 PD European 0
Hill-Burns et al. [163] 2014 4235:2782 Familial and sporadicPD European 4
Nalls et al. [137] 2014 19061:100833 PD European 24
Hu et al. [164] 2016 250:250 PD East Asian 0
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Hill-Burns et al. [165] 2016 1168:0 Familial PD age ofonset European 2
Siitonen et al. [166] 2017 403:1650 Early-onset PD Finnish 13
Foo et al. [167] 2017 5904:30831 PD East Asian 3
Chang et al. [168] 2017 26035:403190 PD European 41
Wallen et al. [169] 2018 2676:0 PD age of onset European 1
Blauwendraat et al. [170] 2019 28568:0 PD age of onset European 2
Bandres-Ciga et al. [171] 2019 4783:3066 PD and PD age ofonset European 5
Nalls et al. [18] 2019 37688(plus 18618 proxycases):1417791 PD European 90
Ryu et al. [172] 2020 741:0 Motor complicationsof PD East Asian 1
Cha et al. [173] 2020 200:0 PD motor response tozonisamide East Asian 1
Tan et al. [174] 2020 2755:0 PD progression European 1






4.1. Disease-Modifying Agents for PD
A disease-modifying agent in PD would be one that slows or stops the processes
leading to neuronal loss. Where there is a single gene abnormality that greatly increases the
risk of PD, strategies targeted at that variant and its biological consequences are appealing.
This is particularly the case for GBA and LRRK2 because they are so much more common
than other monogenic causes of PD. However, any successful agents may only be effective
in that group of patients who harbour a variant and so applicability to idiopathic PD is not
guaranteed. We summarise some of the therapies whose targets have been informed by
PD genetics that are currently under evaluation for the disease-modification for PD.
4.1.1. GBA
While Gaucher disease can be managed with enzyme replacement, GCase does not
cross the blood brain barrier so this is not a viable option in PD [175]. Instead, small
molecules that are able to cross the blood-brain barrier and enhance the action of GCase are
being explored. Currently two agents are registered in phase II clinical trials. The first is
ambroxol, which is a small molecule chaperone of GCase that is already in clinical use as a
cough linctus medicine. It is well-tolerated and has been shown to increase levels of GCase
protein in the CSF of 17 individuals with PD (8 with GBA variants) [176]. A blinded placebo-
controlled trial is underway to assess whether ambroxol is able to improve cognition in
PD dementia [NCT02914366] and is expected to complete in December 2021 [177], whilst a
further phase III clinical trial evaluating the outcome in PD itself is planned. The second
is venglustat, a small molecule inhibitor of glucosylceramide synthase which catalyses
production of the substrate for GCase and has shown efficacy in mouse GBA and SNCA
models of neurodegeneration [178]. Disappointingly, a phase II trial showed that although
a reduction in glucosylceramide was demonstrated in CSF, no clinical difference was
demonstrated comparted to controls (in fact, a non-significant deterioration was seen in the
intervention arm) [179]. A third approach is the use of gene therapy, whereby a viral vector
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injected directly into CSF is used to restore the wildtype GBA sequence. The limitation of
such approaches to date has been the inability to achieve sufficient transfection in the target
organ. A phase I study is currently recruiting to evaluate PR001A, a viral vector-based
therapy to deliver GBA which rescues GCase activity and reduces α-synuclein levels in
cell and mouse models [180], in patients with moderate to severe PD and GBA variants
(NCT04127578). Preliminary results evaluation are expected in mid-2021.
4.1.2. LRRK2
As already mentioned, inhibition of LRRK2 is an attractive therapeutic strategy as
pathogenic variants cause overactivation of the kinase domain and loss of function vari-
ants in humans have no associated disease phenotypes. Moreover, a wide range of small
molecule kinase inhibitors have been developed for use in other diseases [181]. Two
molecules have emerged from pre-clinical testing that appear to offer suitable pharma-
cokinetic profiles and have completed phase I studies (NCT03710707, NCT04056689). The
molecule DNL151 has recently been shown to be well tolerated in healthy volunteers and
people with PD and demonstrated inhibition of LRRK2 function [182]. An alternative strat-
egy targeting LRRK2 overactivity is using antisense oligonucleotides to target mRNA for
degradation. Intrathecal administration may also avoid off-target effects in other organs. A
preclinical study in mice showed that centrally delivered LRRK2 antisense oligonucleotide
reduced α-synuclein aggregates and increased dopaminergic neurons, without effects on
the kidneys or lungs [183]. A phase I study of a LRRK2 antisense oligonucleotide (BIIB094)
in people with PD is registered and due to complete in 2023 [NCT03976349].
4.1.3. SNCA
As well as these studies specifically targeting GBA and LRRK2 cellular processes,
there are a range of compounds that target α-synuclein which could be beneficial in those
with SNCA variants but also, importantly, those with idiopathic PD. Immunotherapy ap-
proaches attempt to remove toxic forms of α-synuclein using antibodies which are either
passively administered or actively stimulated via vaccination. Two α-synuclein antibodies,
prazinezumab and cinpanemab have progressed to phase II clinical trials (NCT03100149
and NCT03318523). The α-synuclein peptide mimic, PD01A, which stimulates an im-
mune response has been shown to be well tolerated in a phase I study of people with
PD [184]. A phase II trial is intended but not yet registered. As well as immunotherapy
techniques, molecules that directly inhibit aggregation of α-synuclein are being evaluated.
Phase II studies are registered for the molecules ANVS-401 (NCT04524351) and ENT-01
(NCT03781791). However, nilotinib, which is used in chronic myeloid leukaemia and has
been shown to accelerate α-synuclein degradation, showed no efficacy [185].
4.1.4. Mitochondria
Genetic and environmental evidence have implicated mitochondrial dysfunction
in PD and strategies that enhance mitophagy are likely to be beneficial to all forms of
PD. Three repurposed oral medications that improve mitochondrial function are being
assessed in phase II trials of idiopathic PD – ursodeoxycholic acid (NCT03840005 [186] ),
terazosin(NCT03905811) and nicotinamide (NCT03568968). In addition, the novel agent
EPI-589 is being assessed in a phase II trial of both idiopathic PD and genetic forms of PD
that alter mitochondrial function (NCT02462603).
4.2. Pharmacogenomics
Genetics can allow for selection of treatments for genetically stratified disease sub-
groups. Both PD and diabetes manifest clinical features when the action of a chemical
messenger (dopamine in PD and insulin in diabetes) is reduced. Diabetes therefore serves
as a useful analogy for how our current knowledge of PD genetics may one day be used to
optimise clinical care and management [187].
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A major success in the field of diabetes genetics has been the recognition that certain
monogenic causes of diabetes are best treated by specific treatments. In particular, the
discovery that patients with activating variants in the ABCC8 and KCNJ11 [188] genes
respond better to sulfonylurea medications than to insulin allowed individuals with these
variants to stop insulin injections [189]. Maturity onset diabetes of the young (MODY) is
another monogenic form of diabetes which presents in early adulthood and typically can be
managed with oral hypoglycaemic medications. Genetic stratification of MODY subtypes
has allowed for homogenous cohort studies and evidence that certain medications are
preferable in specific gene variants [190,191]. Indeed, in the case of MODY due to GCK mu-
tations, it has been possible to determine that no treatment at all is necessary [192]. Finally,
the polygenic type 1 diabetes risk score can be used as one domain to help differentiate
type 1 from type 2 diabetes and therefore determine whether an individual is likely to
require insulin treatment [193].
In PD, choice of treatment depends on a range of factors including patient preference
and risk of side effects. However, prediction of side-effects is difficult and some can have
extremely serious consequences for an individual (e.g., impulse control disorders). The
ability to accurately predict serious side effects, as well as likely response, would be of
great benefit to individual patients. A large number of common variants in genes related
to dopamine action and metabolism have been associated with medication effectiveness
and side effects in PD. These include dopamine receptor genes (DRD1, DRD2, DRD3,
DRD4), dopamine transporter gene (SLC6A3) and the catechol-O-methyltransferase gene
(COMT) [194]. However, many of these association studies have been small in number
and focus on a subset of candidate genes. Moreover, some have shown contradictory
findings [195,196].
More recent studies have evaluated genome-wide common variants in an hypothesis-
free method which have the potential to identify novel genetic modifiers of medication
response [173]. Using genotype data in addition to clinical parameters has been shown to
significantly improve the ability to predict the occurrence of impulse control disorders in
people with a recent diagnosis of PD and a mean follow up of 2.2 years (AUC increased
from 0.64 to 0.76). Indeed the heritability of impulse control disorder was estimated at 57%,
suggesting a predominant genetic component [197]. In contrast, in a retrospective study
of people with PD looking at the time to develop L-DOPA induced motor complications,
addition of genotype to clinical data did not lead to any improvement in the model [198].
A recent systematic review of treatment in monogenic forms of PD highlights the
challenges in drawing conclusions about the best treatment for each subtype [199]. Data
were available for 2226 patients, with the majority being those with PRKN (1002) or LRRK2
(820) variants. Overall 420 variants in 6 genes (SNCA, LRRK2, VPS35, PRKN, PINK1, PARK7)
were identified. There were very high rates of missing data for doses and specific adverse
effects. Overall the treatment efficacies and side-effects appear to be broadly similar to that
of idiopathic PD but conclusions regarding rare variants and non-L-DOPA therapies should
be treated with caution. Several groups have demonstrated poorer outcomes of deep brain
stimulation surgery in those with Parkinson’s who carrying a GBA variant, with some
suggesting that in these cases the benefits of surgery do not outweigh the risk and hence,
other less invasive advanced PD therapies should be selected in these cases [200,201].
5. Selecting Appropriate PD Cohorts for Clinical Trials
Interventional clinical trial arms should be matched so that they only differ in terms
of exposure to the intervention. Any difference, including genetic variation, between the
arms can lead to false negative or false positive results. We know that some forms of
monogenic PD progress at different rates (e.g., GBA-PD tends to have faster motor and
cognitive progression then idiopathic PD). In addition, a higher PD risk PRS has been
associated with faster motor progression as assessed by Hoehn & Yahr and UPDRS-III
scores, which are commonly used as endpoints in clinical trials [202]. Indeed, in predictions
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of PD progression using machine learning models, genetic variation was a better predictor
than imaging or CSF biomarkers [203].
Not accounting for genetic variation has the potential to inadvertently lead to mis-
matched clinical trial arms. A study of simulated clinical trial scenarios using genetic
data from 5851 people with PD estimated that the average PRS varied by up 22% in trials
containing up to 1000 individuals. Further analysis of virtual cohorts showed that for
trials with 50 individuals and an intervention that reduced the MDS-UPDRS by 0.5/year,
over one third would report false negative results as a result of genetically unbalanced
arms [204]. Although these findings could be partially mitigated by larger sample sizes
and longer follow ups, these strategies have implications in terms of cost and practicality.
In principle, balancing clinical trial arms by genetics could lead to better evaluation of
any intervention, although this would require baseline genotyping of all participants and
appropriate consenting.
Recruitment of specific genetic risk factors for PD (for example only individuals
with LRRK2 p.G2019S PD) could enable more genetically stratified cohorts. This can also
allow for targeted therapies to be studied as currently being recruited for LRRK2- and
GBA-targeted compounds. However, we know that the PRS and other genetic factors still
modify progression in these groups [114,205]. Conversely, as our understanding of the
genetics underlying PD risk and progression evolves, balancing trial arms may become
increasingly difficult, requiring an unattainably large pool of potential participants to
draw from.
As well as balancing trial arms, there is potential for using genetics to recruit cohorts
that progress faster, either because of monogenic risk or high PRS. Whereas for an individ-
ual the knowledge that certain groups progress faster on average may be disconcerting
and unhelpful, for a clinical trial cohort this is useful information. Recruiting a cohort
of GBA carriers, for instance, could reduce the follow up required for trials to meet their
endpoints, thereby reducing cost, minimising participant burden and accelerating drug
discovery [206]. Conversely, if indeed LRRK2-PD has a slower rate of progression, a larger
trial size would be required.
Prodromal PD
A major challenge in trials of all neurodegenerative conditions is recruiting individuals
at an early stage of disease who have the most to gain from disease-modifying therapies
[the so-called ‘window of opportunity’]. It has been suggested that a combination of
clinical features and biomarkers can be utilised to identify people with pre-symptomatic or
prodromal disease. PD has a well-established prodromal phase with published research
criteria which, since the 2019 update, incorporates PRS and age-related penetrance of
certain GBA and LRRK2 variants [3]. This could potentially be utilised to identify those ‘at
risk’ or with early PD who may respond more favourably to disease-modifying therapies.
That said, the sensitivity and specificity of attempts to stratify the risk of conversion to
PD in at risk populations have to date been disappointing [207–209], with the exception
of those carrying LRRK2 variants [210]. This may reflect the high penetrance [and by
extension hazard ratio] associated with this genetic risk factor.
A number of longitudinal cohorts have studied the pre-symptomatic features of PD
and attempted to identify predictors of conversion to clinical PD, often using a combina-
tion of measures [211–213]. Both LRRK2 and GBA carriers have been shown to exhibit
prodromal PD features such as hyposmia [209], REM sleep behaviour disorder [214] and
dopaminergic loss [215] and/or glial activation on PET imaging. This raises difficult ethical
issues for clinical trials that still remain to be overcome. If an intervention is required
to be taken for many years, then the safety profile of that intervention must be rigor-
ously assessed. Given the range of penetrance risk and progression of PD even within
specific variants, accurate power calculations and recruitment numbers are difficult to
ascertain [216,217].
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6. Concluding Remarks
Over the last 30 years it has been recognised that genetics contributes approximately
25% to the risk of developing PD. Characterisation of the exact genes involved and their
function has enabled identification of relevant biological pathways are involved in its
pathogenesis. This has been the case for both rare monogenic causes of PD and the more
common late-onset polygenic PD. Indeed, there is significant overlap in the genetic risk
factors suggesting shared disease mechanisms. With this increasing wealth of genetic
knowledge, new strategies to assimilate the information and make it available to clinicians,
researchers and patients are being created [218–220]. Whereas the treatment implications
for different forms of monogenic diabetes have driven genetic testing into clinical practice,
this is not yet the case for routine PD care, although examples of this are beginning
to emerge [33,221,222]. While it is possible to provide some information to individual
patients regarding risk of disease and prognosis, the range of predictions creates uncertainty.
Knowledge of genetics has the potential to improve clinical trial design as well as to
generate new and optimise existing therapeutic options for people with PD.
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